Rhythm Pharmaceuticals (RYTM) Accumulated Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Accumulated Expenses data on file, last reported at $80.0 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 34.95% year-over-year to $80.0 million in Q1 2026; TTM through Mar 2026 was $80.0 million, a 34.95% increase from a year earlier, with the FY2025 full-year figure at $83.9 million, up 33.83% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $80.0 million, down from $83.9 million in the prior quarter.
• Over the last five years, Accumulated Expenses for RYTM reached as high as $84.5 million in Q3 2025 and fell as low as $25.2 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $50.9 million across 5 years, with a median of $48.1 million in 2024.
• Across the five-year window, Accumulated Expenses jumped 252.43% in 2022 and increased 0.29% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $32.9 million in 2022, then soared by 46.72% to $48.3 million in 2023, then increased by 29.83% to $62.7 million in 2024, then jumped by 33.83% to $83.9 million in 2025, then declined by 4.54% to $80.0 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $80.0 million in Q1 2026, $83.9 million in Q4 2025, and $84.5 million in Q3 2025.